MCID: HMN021
MIFTS: 52

Human T-Cell Leukemia Virus Type 1

Categories: Blood diseases, Cancer diseases, Immune diseases, Rare diseases, Skin diseases

Aliases & Classifications for Human T-Cell Leukemia Virus Type 1

MalaCards integrated aliases for Human T-Cell Leukemia Virus Type 1:

Name: Human T-Cell Leukemia Virus Type 1 53
Human T Lymphotropic Virus Type 1 53
Htlv-1 53

Classifications:



Summaries for Human T-Cell Leukemia Virus Type 1

NIH Rare Diseases : 53 Human T-cell leukemia virus, type 1 (HTLV-1) is a retroviral infection that affect the T cells (a type of white blood cell). Although this virus generally causes no signs or symptoms, some affected people may later develop adult T-cell leukemia (ATL), HTLV-1 associated myelopathy/tropical spastic paraparesis (HAM/TSP) or other medical conditions. HTLV-1 is spread by blood transfusions, sexual contact and sharing needles. It can also be spread from mother to child during birth or breast-feeding. There is no cure or treatment for HTLV-1 and it is considered a lifelong condition; however, most (95%) infected people remain asymptomatic (show no symptoms) throughout life.

MalaCards based summary : Human T-Cell Leukemia Virus Type 1, also known as human t lymphotropic virus type 1, is related to t-cell leukemia and human t-cell leukemia virus type 2. An important gene associated with Human T-Cell Leukemia Virus Type 1 is CRTC2 (CREB Regulated Transcription Coactivator 2), and among its related pathways/superpathways are GPCR Pathway and IL-2 Pathway. The drugs Zidovudine and Valproic Acid have been mentioned in the context of this disorder. Affiliated tissues include t cells, skin and bone, and related phenotypes are Decreased TP53 mRNA expression and Increased viability with MLN4924 (a NAE inhibitor)

Wikipedia : 76 Human T-cell lymphotropic virus type 1 or human T-lymphotropic virus type 1 (HTLV-I), also called the... more...

Related Diseases for Human T-Cell Leukemia Virus Type 1

Diseases in the T-Cell Leukemia family:

Adult T-Cell Leukemia Acute T Cell Leukemia
Human T-Cell Leukemia Virus Type 1 Human T-Cell Leukemia Virus Type 2
Human T-Cell Leukemia Virus Type 3 Leukemia, B-Cell, Chronic
Leukemia, T-Cell, Chronic

Diseases related to Human T-Cell Leukemia Virus Type 1 via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 134)
# Related Disease Score Top Affiliating Genes
1 t-cell leukemia 30.5 CCND2 CNTN2 CREB1 CREBBP CRTC1 CRTC2
2 human t-cell leukemia virus type 2 29.6 CNTN2 CREB1 CREBBP EP300 NFKB1
3 infective dermatitis associated with htlv-1 12.2
4 htlv-1 associated myelopathy/tropical spastic paraparesis 11.9
5 retrovirus-associated myelopathy 11.4
6 leukemia 11.3
7 pars planitis 11.0
8 intermediate uveitis 11.0
9 adult t-cell leukemia 10.7
10 human immunodeficiency virus type 1 10.4
11 myelopathy, htlv-1-associated 10.4
12 lymphoma 10.4
13 tropical spastic paraparesis 10.4
14 spastic paraparesis 10.4
15 dermatitis 10.4
16 strongyloidiasis 10.3
17 hepatitis 10.3
18 hepatitis c 10.3
19 hepatitis c virus 10.2
20 diffuse large b-cell lymphoma 10.2
21 multiple sclerosis 10.2
22 chromosome 16p13.3 deletion syndrome, proximal 10.1 CREB1 CREBBP EP300
23 leukemia, chronic lymphocytic 2 10.0
24 leukemia, chronic lymphocytic 10.0
25 retinoblastoma 10.0
26 rheumatoid arthritis 10.0
27 small cell cancer of the lung 10.0
28 lung cancer 10.0
29 immunodeficiency-centromeric instability-facial anomalies syndrome 1 10.0
30 arthritis 10.0
31 t-cell large granular lymphocyte leukemia 10.0
32 lymphocytic leukemia 10.0
33 gastric lymphoma 10.0
34 diphtheria 10.0
35 graves' disease 10.0
36 uveitis 10.0
37 arthropathy 10.0
38 borna disease 10.0
39 herpes simplex 10.0
40 viral infectious disease 10.0
41 stomatitis 10.0
42 glioblastoma 10.0
43 large granular lymphocyte leukemia 10.0
44 leukemia, b-cell, chronic 10.0
45 depression 10.0
46 rubinstein-taybi syndrome 1 10.0 CREBBP EP300
47 hepatocellular carcinoma 10.0
48 ataxia-telangiectasia 10.0
49 myelofibrosis 10.0
50 leukemia, acute lymphoblastic 10.0

Graphical network of the top 20 diseases related to Human T-Cell Leukemia Virus Type 1:



Diseases related to Human T-Cell Leukemia Virus Type 1

Symptoms & Phenotypes for Human T-Cell Leukemia Virus Type 1

GenomeRNAi Phenotypes related to Human T-Cell Leukemia Virus Type 1 according to GeneCards Suite gene sharing:

26
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased TP53 mRNA expression GR00389-S-5 9.13 CREB1 JUN NFKB1
2 Increased viability with MLN4924 (a NAE inhibitor) GR00250-A-3 9.02 BST2 CDKN1A EP300 JUN NFKB1

MGI Mouse Phenotypes related to Human T-Cell Leukemia Virus Type 1:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 behavior/neurological MP:0005386 10.06 CCND2 CDKN1A CNTN2 CREB1 CREBBP CRTC1
2 homeostasis/metabolism MP:0005376 10.06 CCND2 CDKN1A CREB1 CREBBP CRTC1 CRTC2
3 endocrine/exocrine gland MP:0005379 10.02 CCND2 CDKN1A CREB1 CREBBP CRTC1 EP300
4 liver/biliary system MP:0005370 9.8 CCND2 CDKN1A CREBBP CRTC2 CRTC3 JUN
5 muscle MP:0005369 9.7 CDKN1A CREB1 CREBBP CRTC3 EP300 GLI2
6 nervous system MP:0003631 9.61 CCND2 CDKN1A CNTN2 CREB1 CREBBP EP300
7 respiratory system MP:0005388 9.17 CDKN1A CREB1 CREBBP EP300 GLI2 JUN

Drugs & Therapeutics for Human T-Cell Leukemia Virus Type 1

Drugs for Human T-Cell Leukemia Virus Type 1 (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 125)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Zidovudine Approved Phase 4,Phase 2,Phase 3,Early Phase 1 30516-87-1 35370
2
Valproic Acid Approved, Investigational Phase 4,Phase 3,Not Applicable 99-66-1 3121
3
Peginterferon alfa-2b Approved Phase 4,Phase 2 99210-65-8, 215647-85-1
4 Anticonvulsants Phase 4,Phase 3,Phase 1,Not Applicable
5 Neurotransmitter Agents Phase 4,Phase 3,Phase 1,Not Applicable
6 Immunoglobulin G Phase 4,Phase 1,Phase 2
7 Antibodies Phase 4,Phase 1,Phase 2
8 Immunoglobulins Phase 4,Phase 1,Phase 2
9 Immunologic Factors Phase 4,Phase 2,Phase 3,Phase 1
10 Immunosuppressive Agents Phase 4,Phase 2,Phase 3,Phase 1
11 Antimetabolites Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1
12 Antiviral Agents Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1
13 Nucleic Acid Synthesis Inhibitors Phase 4,Phase 2,Phase 3,Early Phase 1
14 Psychotropic Drugs Phase 4,Phase 3,Not Applicable
15 Anti-HIV Agents Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1
16 Reverse Transcriptase Inhibitors Phase 4,Phase 2,Phase 3,Early Phase 1
17 Central Nervous System Depressants Phase 4,Phase 3,Not Applicable
18 Anti-Infective Agents Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1
19 Antimanic Agents Phase 4,Phase 3,Not Applicable
20 Interferon-alpha Phase 4,Phase 2
21 Anti-Retroviral Agents Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1
22 interferons Phase 4,Phase 2
23 Tranquilizing Agents Phase 4,Phase 3,Not Applicable
24 GABA Agents Phase 4,Phase 3,Not Applicable
25
Lamivudine Approved, Investigational Phase 2, Phase 3,Phase 3 134678-17-4 60825
26
Pentoxifylline Approved, Investigational Phase 3 6493-05-6 4740
27
Miconazole Approved, Investigational, Vet_approved Phase 2, Phase 3 22916-47-8 4189
28
Lopinavir Approved Phase 2, Phase 3 192725-17-0 92727
29
Ritonavir Approved, Investigational Phase 2, Phase 3 155213-67-5 392622
30 Vasodilator Agents Phase 3
31 Phosphodiesterase Inhibitors Phase 3
32 Free Radical Scavengers Phase 3
33 Radiation-Protective Agents Phase 3
34 Protective Agents Phase 3
35 Platelet Aggregation Inhibitors Phase 3
36 Antioxidants Phase 3
37 Calcineurin Inhibitors Phase 2, Phase 3
38 Antifungal Agents Phase 2, Phase 3
39 Dermatologic Agents Phase 2, Phase 3
40 Cyclosporins Phase 2, Phase 3
41 Antirheumatic Agents Phase 2, Phase 3,Phase 1
42 HIV Integrase Inhibitors Phase 2, Phase 3,Phase 1,Early Phase 1
43 Integrase Inhibitors Phase 2, Phase 3,Phase 1,Early Phase 1
44 Raltegravir Potassium Phase 2, Phase 3,Phase 1,Early Phase 1
45 Cytochrome P-450 Enzyme Inhibitors Phase 2, Phase 3
46 HIV Protease Inhibitors Phase 2, Phase 3
47 Cytochrome P-450 CYP3A Inhibitors Phase 2, Phase 3
48
protease inhibitors Phase 2, Phase 3
49
Interferon beta-1a Approved, Investigational Phase 2 145258-61-3 6438354
50
Lenalidomide Approved Phase 2,Phase 1 191732-72-6 216326

Interventional clinical trials:

(show top 50) (show all 58)
# Name Status NCT ID Phase Drugs
1 MP Diagnostics HTLV Blot 2.4 Post-Market Clinical Study Completed NCT03226119 Phase 4
2 Pilot Study of Combination Therapy With CHOP-Zenapax (CHOP-daclizumab) Completed NCT01418430 Phase 4 CHOP-daclizumab
3 Zidovudine, Interferon Alfa-2b, PEG-Interferon Alfa-2b in Patients With HTLV-I Associated Adult T-Cell Leukemia/Lymphoma Terminated NCT00854581 Phase 4 Valproic Acid;Zidovudine
4 Efficacy and Safety of Tamibarotene(AM80H) for HTLV-1 Associated Myelopathy/ Tropical Spastic Paraparesis (HAM/TSP) Unknown status NCT01343355 Phase 2, Phase 3 Tamibarotene
5 Zidovudine Plus Lamivudine in HTLV-I-associated Myelopathy: a Randomised Trial Completed NCT00272480 Phase 2, Phase 3 Zidovudine/lamivudine
6 Use of Pentoxifylline in Human T-lymphotropic Virus Type-1 (HTLV-1) Diseases Completed NCT01472263 Phase 3 Pentoxifylline;Placebo
7 Ciclosporin in HTLV-1 Associated Myelopathy/ Tropical Spastic Paraparesis (HAM/TSP) Completed NCT00773292 Phase 2, Phase 3 ciclosporin
8 Use Of Valproid Acid To Treat Tropical Spastic Paraparesis/HTLV-1-Associated Myelopathy (TSP/HAM) Completed NCT00681980 Phase 3 Valproic acid;costicosteroids;valproid acid plus corticosteroids
9 Antiretroviral Regimens Containing Raltegravir for Prophylaxis of Mother-to-child-transmission of HIV Infection Recruiting NCT01854762 Phase 2, Phase 3 Raltegravir;Lopinavir/Ritonavir
10 Long-term Safety and Efficacy Follow-up of Subjects Treated With GSK2696277 for Transfusion Dependent Beta-thalassemia in San Raffaele Telethon Institute of Gene Therapy-Beta Thalassemia (TIGET-BTHAL) Study Recruiting NCT03275051 Phase 2, Phase 3
11 A Study of KW-0761 in Subjects With HTLV-1 Associated Myelopathy (HAM) Active, not recruiting NCT03191526 Phase 3 KW-0761 0.3 mg/kg IV;Placebo (saline)
12 Recombinant Human Interferon Beta-1a (Avonex) for the Treatment of Patients With HTLV-1-Associated Myelopathy (HAM) Completed NCT00001785 Phase 2 Recombinant human interferon beta-1a
13 Lenalidomide in HTLV-1 Adult T-Cell Leukemia Completed NCT01274533 Phase 2 Lenalidomide
14 Combination Chemotherapy Followed By Antiviral Therapy and Interferon Alfa in Treating Patients With HTLV-1-Related Adult T-Cell Leukemia/Lymphoma Completed NCT00041327 Phase 2 Etoposide;cyclophosphamide;doxorubicin hydrochloride;lamivudine;prednisone;vincristine sulfate;zidovudine
15 Anti-Tac for Treatment of Leukemia Completed NCT00001941 Phase 1, Phase 2
16 EPOCH Chemotherapy and Bortezomib for Associated T-Cell Leukemia Lymphoma Completed NCT01000285 Phase 1, Phase 2 Bortezomib;Etoposide;Vincristine;Doxorubicin;Prednisone;Cyclophosphamide;Raltegravir
17 Campath-1H for Treating Adult T-Cell Leukemia/Lymphoma Completed NCT00061048 Phase 2
18 Phase II Study of the Efficacy and Toxicity of Ontak(Registered Trademark) (Denileukin Diftitox) in the Therapy of Adult T-Cell Leukemia Completed NCT00117845 Phase 2
19 Study of Pralatrexate & Gemcitabine With B12 & Folic Acid to Treat Relapsed/Refractory Lymphoproliferative Malignancies Completed NCT00481871 Phase 1, Phase 2 Pralatrexate Injection;Gemcitabine Hydrochloride
20 Ruxolitinib for Adult T-Cell Leukemia Recruiting NCT01712659 Phase 2 Ruxolitinib;ruxolitinib
21 Belinostat Therapy With Zidovudine for Adult T-Cell Leukemia-Lymphoma Recruiting NCT02737046 Phase 2 Belinostat;Zidovudine;Interferon-Alfa-2b;Pegylated Interferon-Alfa-2b
22 Nivolumab in Treating Patients With Relapsed or Refractory Peripheral T-cell Lymphoma Recruiting NCT03075553 Phase 2
23 Nivolumab in Treating Patients With HTLV-Associated T-Cell Leukemia/Lymphoma Active, not recruiting NCT02631746 Phase 2
24 Phase II Trial of LMB-2, Fludarabine and Cyclophosphamide for Adult T-Cell Leukemia Active, not recruiting NCT00924170 Phase 1, Phase 2 LMB-2;Fludarabine;Cyclophosphamide
25 The HAM Infliximab Study Terminated NCT00823641 Phase 2 Infliximab
26 Trial to Assess Effect of Raltegravir on HTLV-1 Proviral Load Withdrawn NCT01620736 Phase 2 Raltegravir
27 Immunotherapy of Natural Killer(NK) Cells in Human T Lymphotropic Virus Type 1(HTLV-1) Associated Myelopathy(HAM) Unknown status NCT02961712 Phase 1
28 A Randomized, Placebo-Controlled Study to Assess the Efficacy of Propantheline for the Treatment of Overactive Bladder Unknown status NCT01640002 Phase 1 Propantheline Bromide;Placebo
29 Hu Mik-Beta-1 to Treat HTLV-1-Associated Myelopathy/Tropical Spastic Paraparesis Completed NCT00076843 Phase 1 Hu MiK-Beta-1
30 A Phase I, Multicenter, Open-label, Dose-escalation Study to Assess the Safety of Lenalidomide in Patients With Advanced Adult T-cell Leukemia-lymphoma and Peripheral T-cell Lymphomaperipheral T-cell Lymphoma Completed NCT01169298 Phase 1 Lenalidomide
31 Evaluation of the MP Diagnostics HTLV Blot 2.4 Unknown status NCT01467024
32 Notification of Donors With Positive Microbiology Markers Unknown status NCT01050881
33 Influence of IL28B Genetic Variation on the Phenotype Infection of HTLV-1 Completed NCT01754311
34 Raltegravir for HAM/TSP Completed NCT01867320 Early Phase 1 Raltegravir
35 Urological Physical Therapy in HTLV-1 With Urinary Symptoms Completed NCT01651819 Not Applicable
36 Natural History of HTLV-I Infection: Prospective Follow-up of a Cohort of Blood Donors in Jamaica Completed NCT00339807
37 A Study of Familial and Genetic Aspects of Adult T-Cell: Leukemia/Lymphoma , Tropical Spastic Paraparesis, and Infective Dermatitis Completed NCT00340821
38 MRI Brain Studies in Patients With HTLV-1 Associated Myelopathy/Tropical Spastic Paraparesis Completed NCT00034723
39 Sensorimotor Exercises in Virtual Reality Platform in Individuals With Human T-lymphotropic Virus Completed NCT02877030 Not Applicable
40 Dual Algorithm Post Market Clinical Study Completed NCT03146013
41 Epidemic History and Iatrogenic Transmission of Blood-borne Viruses in Mid-20th Century Kinshasa Completed NCT02439918
42 Study of Adult T-Cell Leukemia/Lymphoma Among Carriers of HTLV-1 Completed NCT00339638
43 Neuroimmunology Branch Repository Completed NCT01581567
44 Retrovirus Epidemiology Donor Study I (REDS I) Completed NCT00005278
45 Idiopathic CD4 Lymphocytopenia Completed NCT02113930
46 Gene Expression in Samples From Patients With T-Cell Acute Lymphoblastic Leukemia Completed NCT01520246
47 Assessment of Patients With Multiple Sclerosis (MS) Completed NCT00001156
48 Late Effects of Treatment for Sarcomas in Children Completed NCT00006515
49 Improving Blood Safety and HIV Testing in Brazil Completed NCT01681420 Not Applicable
50 Retrovirus Epidemiology Donor Study-II (REDS-II) Completed NCT00097006

Search NIH Clinical Center for Human T-Cell Leukemia Virus Type 1

Genetic Tests for Human T-Cell Leukemia Virus Type 1

Anatomical Context for Human T-Cell Leukemia Virus Type 1

MalaCards organs/tissues related to Human T-Cell Leukemia Virus Type 1:

41
T Cells, Skin, Bone, B Cells, Liver, Lung, Thyroid

Publications for Human T-Cell Leukemia Virus Type 1

Articles related to Human T-Cell Leukemia Virus Type 1:

(show top 50) (show all 764)
# Title Authors Year
1
HIV virological failure in a patient with human T-lymphotropic virus type 1-associated leukemia. ( 30507628 )
2019
2
Molecular targeting for treatment of human T-lymphotropic virus type 1 infection. ( 30551530 )
2019
3
Complete Sequences of the Human T-Cell Leukemia Virus Type 1 Proviral Genomes from Newly Established Adult T-Cell Leukemia Cell Lines in Oita Prefecture, Japan. ( 29930027 )
2018
4
Control of Human T-Cell Leukemia Virus Type 1 (HTLV-1) Infection by Eliminating Envelope Protein-Positive Cells with Recombinant Vesicular Stomatitis Viruses Encoding HTLV-1 Primary Receptor. ( 29212930 )
2018
5
In vitro basal T-cell proliferation among asymptomatic Human T cell Leukemia Virus type 1 patients co-infected with hepatitis C and/or Human Immunodeficiency Virus type 1. ( 29499169 )
2018
6
The human T-cell leukemia virus type-1 p30<sup>II</sup> protein activates p53 and induces the TIGAR and suppresses oncogene-induced oxidative stress during viral carcinogenesis. ( 29462755 )
2018
7
Natural Course of Human T-Cell Leukemia Virus Type 1 Proviral DNA Levels in Carriers During Pregnancy. ( 29346571 )
2018
8
Fine-scale geographic clustering pattern of human T-cell leukemia virus type 1 infection among blood donors in Kyushu-Okinawa, Japan. ( 29900555 )
2018
9
Critical Role of the Human T-Cell Leukemia Virus Type 1 Capsid N-Terminal Domain for Gag-Gag Interactions and Virus Particle Assembly. ( 29695435 )
2018
10
Impact of Hepatitis B Virus Coinfection on Human T-Lymphotropic Virus Type 1 Clonality in an Indigenous Population of Central Australia. ( 30307560 )
2018
11
Distinct Pathway of Human T-Cell Leukemia Virus Type 1 Gag Punctum Biogenesis Provides New Insights into Enveloped Virus Assembly. ( 30181245 )
2018
12
Non-canonical translation initiation of the spliced mRNA encoding the human T-cell leukemia virus type 1 basic leucine zipper protein. ( 30215750 )
2018
13
Human T-cell leukemia virus type 1 Gag domains have distinct RNA-binding specificities with implications for RNA packaging and dimerization. ( 30217825 )
2018
14
Non-Structural Proteins from Human T-cell Leukemia Virus Type 1 in Cellular Membranes-Mechanisms for Viral Survivability and Proliferation. ( 30413005 )
2018
15
The Human T-Cell Leukemia Virus Type 1 Basic Leucine Zipper Factor Attenuates Repair of Double-Stranded DNA Breaks via Nonhomologous End Joining. ( 29769340 )
2018
16
Inhibition of Tunneling Nanotube (TNT) Formation and Human T-cell Leukemia Virus Type 1 (HTLV-1) Transmission by Cytarabine. ( 30042514 )
2018
17
Dendritic Cells Promote the Spread of Human T-Cell Leukemia Virus Type 1 via Bidirectional Interactions with CD4+ T Cells. ( 30048652 )
2018
18
Development of reference material with assigned value for human T-cell leukemia virus type 1 quantitative PCR in Japan. ( 30125970 )
2018
19
Rate of positive autoimmune markers in Human T lymphotropic virus type 1 carriers: a case-control study from Iran. ( 28261958 )
2018
20
Infective dermatitis associated with human T-lymphotropic virus type 1 infection in Adelaide, South Australia. ( 28832919 )
2018
21
Human T-lymphotropic virus type 1 infection and solid organ transplantation. ( 29380451 )
2018
22
Switching and loss of cellular cytokine producing capacity characterize in vivo viral infection and malignant transformation in human T- lymphotropic virus type 1 infection. ( 29444188 )
2018
23
Can we reduce the incidence of adult T-cell leukaemia/lymphoma? Cost-effectiveness of human T-lymphotropic virus type 1 (HTLV-1) antenatal screening in the United Kingdom. ( 29676441 )
2018
24
Polymorphic Nature of Human T-Cell Leukemia Virus Type 1 Particle Cores as Revealed through Characterization of a Chronically Infected Cell Line. ( 28615198 )
2017
25
IL-10-mediated signals act as a switch for lymphoproliferation in Human T-cell leukemia virus type-1 infection by activating the STAT3 and IRF4 pathways. ( 28910419 )
2017
26
Flow cytometric-based protocols for assessing anti-MT-2 IgG1 reactivity: High-dimensional data handling to define predictors for clinical follow-up of Human T-cell Leukemia virus type-1 infection. ( 28212879 )
2017
27
Human T-Cell Leukemia Virus Type 1 Infection and Adult T-Cell Leukemia. ( 29052136 )
2017
28
Human T-cell leukemia virus type 1 infects multiple lineage hematopoietic cells in vivo. ( 29186194 )
2017
29
Effects of expressing human T-cell leukemia virus type 1 (HTLV-I) oncoprotein Tax on DOK1, DOK2 and DOK3 gene expression in mice. ( 28302940 )
2017
30
HLA-DMB restricts human T-cell leukemia virus type-1 (HTLV-1) protein expression via regulation of ATG7 acetylation. ( 29089548 )
2017
31
Proviral Features of Human T Cell Leukemia Virus Type 1 in Carriers with Indeterminate Western Blot Analysis Results. ( 28701419 )
2017
32
Failure to prevent human T-cell leukemia virus type 1 mother-to-child transmission in Japan. ( 28211219 )
2017
33
Perturbation of Human T-Cell Leukemia Virus Type 1 Particle Morphology by Differential Gag Co-Packaging. ( 28753950 )
2017
34
Human T Cell Leukemia Virus Type 1: Persistence and Pathogenesis. ( 29144838 )
2017
35
Human T Cell Leukemia Virus Type 1 and Eye Diseases. ( 28263674 )
2017
36
RNA stability regulates human T cell leukemia virus type 1 gene expression in chronically-infected CD4 T cells. ( 28478312 )
2017
37
Adult T-cell leukemia/lymphoma in a Peruvian hospital in human T-lymphotropic virus type 1 (HTLV-1) positive patients. ( 28251608 )
2017
38
Comparative performances of serologic and molecular assays for detecting human T lymphotropic virus type 1 and type 2 (HTLV-1 and HTLV-2) in patients infected with human immunodeficiency virus type 1 (HIV-1). ( 28343818 )
2017
39
Erratum to: Endemic impact of human T cell leukemia virus type 1 screening in bone allografts. ( 27770291 )
2017
40
Human T-Lymphotropic Virus Type-1-Associated Myelopathy/Tropical Spastic Paraparesis: The First Case Report in Southeast Asia. ( 28343405 )
2017
41
Acute progressive human T-lymphotropic virus type 1-associated myelopathy with Sjögren's syndrome: Cause or coincidence? ( 28131215 )
2017
42
Isolated bladder dysfunction in human T lymphotropic virus type 1 infection: 10 years of follow-up. ( 27815322 )
2017
43
Infection of defective human T-lymphotropic virus type 1. ( 28070874 )
2017
44
Seroprevalence and geographical distribution of human T-lymphotropic virus type 1 among volunteer blood donors in endemic areas of Iran. ( 28137274 )
2017
45
Prevalence and risk factors for Human T-Lymphotropic Virus Type 1 (HTLV-1) among maintenance hemodialysis patients. ( 28202003 )
2017
46
Repression of Human T-lymphotropic virus type 1 Long Terminal Repeat sense transcription by Sp1 recruitment to novel Sp1 binding sites. ( 28256531 )
2017
47
Quantitative Analysis of Human T-Lymphotropic Virus Type 1 (HTLV-1) Infection Using Co-Culture with Jurkat LTR-Luciferase or Jurkat LTR-GFP Reporter Cells. ( 28357661 )
2017
48
MAIT cells are reduced in frequency and functionally impaired in human T lymphotropic virus type 1 infection: Potential clinical implications. ( 28384290 )
2017
49
Prevalence of Human T-lymphotropic virus type 1 (HTLV-1) Infection in Patients with Hematologic Disorders and Non-Hematologic Malignancies in a Tertiary Referral Hospital. ( 28412826 )
2017
50
Human T-lymphotropic virus type 1 infection and disease in Spain. ( 28700391 )
2017

Variations for Human T-Cell Leukemia Virus Type 1

Expression for Human T-Cell Leukemia Virus Type 1

Search GEO for disease gene expression data for Human T-Cell Leukemia Virus Type 1.

Pathways for Human T-Cell Leukemia Virus Type 1

Pathways related to Human T-Cell Leukemia Virus Type 1 according to GeneCards Suite gene sharing:

(show top 50) (show all 102)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.74 CCND2 CDKN1A CREB1 CREBBP EP300 JUN
2
Show member pathways
13.23 ATF1 CREB1 CREBBP EP300 JUN NFKB1
3
Show member pathways
13.06 CREB1 CREBBP EP300 GLI2 JUN NFKB1
4
Show member pathways
13 ATF1 CDKN1A CREBBP EP300 JUN NFKB1
5
Show member pathways
13 CCND2 CDKN1A CREB1 CREBBP CRTC2 EP300
6
Show member pathways
12.96 APOBEC3B BST2 CDKN1A CREB1 CREBBP EP300
7
Show member pathways
12.9 CDKN1A CREB1 CREBBP EP300 JUN NFKB1
8
Show member pathways
12.89 CREB1 CREBBP EP300 JUN NFKB1
9
Show member pathways
12.87 CREB1 CREBBP CRTC1 CRTC2 CRTC3
10
Show member pathways
12.82 ATF1 CDKN1A CREB1 JUN NFKB1
11
Show member pathways
12.81 CCND2 CREBBP EP300 JUN NFKB1 XPO1
12 12.79 CCND2 CDKN1A CREBBP EP300 GLI2 JUN
13
Show member pathways
12.61 CDKN1A CREBBP EP300 NFKB1
14
Show member pathways
12.58 CCND2 CREBBP EP300 JUN
15
Show member pathways
12.56 ATF1 CREB1 JUN NFKB1
16 12.56 CCND2 CDKN1A CREBBP EP300 NFKB1
17
Show member pathways
12.54 CREB1 CREBBP EP300 JUN NFKB1
18
Show member pathways
12.52 CDKN1A CREBBP EP300 JUN NFKB1
19 12.46 CCND2 CREB1 CREBBP JUN
20
Show member pathways
12.46 CDKN1A CREB1 CREBBP EP300
21
Show member pathways
12.44 CCND2 CREB1 CREBBP EP300 JUN NFKB1
22
Show member pathways
12.43 CCND2 CDKN1A CREBBP EP300
23
Show member pathways
12.42 CCND2 CDKN1A CREB1 EP300 NFKB1
24 12.41 CCND2 CDKN1A CREBBP EP300
26
Show member pathways
12.35 ATF1 CREB1 EP300 JUN NFKB1
27 12.34 CCND2 CDKN1A JUN NFKB1
28
Show member pathways
12.33 CREB1 CREBBP EP300 JUN NFKB1
29 12.3 ATF1 CCND2 CDKN1A NFKB1
30 12.28 CREB1 CREBBP EP300 NFKB1
31
Show member pathways
12.26 CREBBP EP300 JUN NFKB1
32
Show member pathways
12.24 CCND2 CDKN1A JUN NFKB1 XPO1
33
Show member pathways
12.19 CREB1 CREBBP JUN NFKB1
34 12.19 CREB1 CREBBP EP300 JUN NFKB1
35
Show member pathways
12.18 CDKN1A EP300 JUN NFKB1
36 12.17 CREB1 CRTC1 JUN NFKB1
37 12.17 CCND2 CDKN1A CREB1 CREBBP EP300 JUN
38
Show member pathways
12.14 CCND2 CDKN1A CREBBP EP300
39 12.13 ATF1 CREB1 EP300 JUN NFKB1
40
Show member pathways
12.13 CREB1 CREBBP CRTC1 CRTC2 CRTC3 EP300
41 12.12 CDKN1A CREBBP EP300 JUN
42 12.11 CDKN1A CREBBP EP300 JUN
43
Show member pathways
12.1 CCND2 CREBBP GLI2 XPO1
44
Show member pathways
12.09 CDKN1A CREBBP EP300 JUN
45
Show member pathways
12.07 CREB1 CREBBP CRTC1 CRTC2 CRTC3
46 12.06 CREB1 JUN NFKB1
47
Show member pathways
12.05 CREBBP EP300 JUN
48
Show member pathways
12.04 CREB1 JUN NFKB1
49
Show member pathways
12.04 ATF1 JUN NFKB1
50 12.04 CCND2 CDKN1A JUN NFKB1

GO Terms for Human T-Cell Leukemia Virus Type 1

Cellular components related to Human T-Cell Leukemia Virus Type 1 according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 nucleus GO:0005634 9.8 APOBEC3B ATF1 CCND2 CDKN1A CREB1 CREBBP
2 transcription factor complex GO:0005667 9.46 ATF1 CREB1 EP300 JUN
3 nucleoplasm GO:0005654 9.44 ATF1 CCND2 CDKN1A CREB1 CREBBP CRTC1
4 cytoplasm GO:0005737 10.03 APOBEC3B BST2 CCND2 CDKN1A CREBBP CRTC1

Biological processes related to Human T-Cell Leukemia Virus Type 1 according to GeneCards Suite gene sharing:

(show all 22)
# Name GO ID Score Top Affiliating Genes
1 negative regulation of transcription by RNA polymerase II GO:0000122 9.95 CREBBP EP300 GLI2 JUN NFKB1 XPO1
2 negative regulation of apoptotic process GO:0043066 9.92 CCND2 CDKN1A GLI2 JUN NFKB1
3 positive regulation of transcription, DNA-templated GO:0045893 9.91 CREB1 CREBBP EP300 GLI2 JUN NFKB1
4 response to drug GO:0042493 9.87 CDKN1A CREB1 JUN XPO1
5 transcription by RNA polymerase II GO:0006366 9.85 ATF1 CREB1 EP300 GLI2 JUN NFKB1
6 response to organic cyclic compound GO:0014070 9.78 ATF1 CDKN1A JUN
7 response to organic substance GO:0010033 9.72 CDKN1A CREB1 JUN
8 circadian rhythm GO:0007623 9.71 CREB1 EP300 JUN
9 protein homotetramerization GO:0051289 9.69 CRTC1 CRTC2 CRTC3
10 stimulatory C-type lectin receptor signaling pathway GO:0002223 9.67 CREBBP EP300 NFKB1
11 rhythmic process GO:0048511 9.62 CREB1 CREBBP CRTC1 EP300
12 positive regulation of long-term synaptic potentiation GO:1900273 9.6 CREB1 CRTC1
13 positive regulation of transcription of Notch receptor target GO:0007221 9.59 CREBBP EP300
14 positive regulation by host of viral transcription GO:0043923 9.58 EP300 JUN
15 response to muscle stretch GO:0035994 9.58 JUN NFKB1
16 positive regulation of type I interferon production GO:0032481 9.58 CREBBP EP300 NFKB1
17 protein acetylation GO:0006473 9.56 CREBBP EP300
18 viral process GO:0016032 9.5 CREB1 CREBBP CRTC1 CRTC2 CRTC3 EP300
19 N-terminal peptidyl-lysine acetylation GO:0018076 9.46 CREBBP EP300
20 positive regulation of DNA replication GO:0045740 9.43 ATF1 GLI2 JUN
21 positive regulation of CREB transcription factor activity GO:0032793 9.33 CRTC1 CRTC2 CRTC3
22 positive regulation of transcription by RNA polymerase II GO:0045944 9.32 ATF1 CREB1 CREBBP CRTC1 CRTC2 CRTC3

Molecular functions related to Human T-Cell Leukemia Virus Type 1 according to GeneCards Suite gene sharing:

(show all 15)
# Name GO ID Score Top Affiliating Genes
1 identical protein binding GO:0042802 9.97 ATF1 BST2 CNTN2 CREB1 JUN NFKB1
2 sequence-specific DNA binding GO:0043565 9.92 ATF1 CREB1 GLI2 JUN NFKB1
3 DNA-binding transcription factor activity GO:0003700 9.88 ATF1 CREB1 CREBBP GLI2 JUN NFKB1
4 transcription regulatory region DNA binding GO:0044212 9.76 CREB1 GLI2 JUN NFKB1
5 chromatin binding GO:0003682 9.73 CREBBP CRTC2 EP300 GLI2 JUN NFKB1
6 RNA polymerase II distal enhancer sequence-specific DNA binding GO:0000980 9.69 CREB1 JUN NFKB1
7 DNA-binding transcription activator activity, RNA polymerase II-specific GO:0001228 9.67 ATF1 CREB1 EP300 JUN
8 transcription coregulator activity GO:0003712 9.65 CREB1 CREBBP EP300
9 transcription factor binding GO:0008134 9.63 CREB1 CREBBP EP300 GLI2 JUN NFKB1
10 transcription factor activity, RNA polymerase II distal enhancer sequence-specific binding GO:0003705 9.61 ATF1 CREB1 JUN
11 acetyltransferase activity GO:0016407 9.55 CREBBP EP300
12 cAMP response element binding GO:0035497 9.54 CREB1 JUN
13 peptide N-acetyltransferase activity GO:0034212 9.32 CREBBP EP300
14 cAMP response element binding protein binding GO:0008140 9.13 CRTC1 CRTC2 CRTC3
15 RNA polymerase II activating transcription factor binding GO:0001102 8.92 CREB1 CREBBP EP300 JUN

Sources for Human T-Cell Leukemia Virus Type 1

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
Content
Loading form....